Sana’s Q4 2025 net loss widened year over year due to fair value adjustments, while research and development and general and administrative expenses declined following portfolio prioritization efforts.
Net loss was 58825000 compared to 49069000 in the prior year period.
Research and development expenses declined to 34924000 from 45145000 year over year.
General and administrative expenses decreased to 12186000 from 17277000.
Cash, cash equivalents, and marketable securities totaled 138382000 at quarter end.
Sana expects its existing cash, cash equivalents, and marketable securities to provide runway into late 2026 while advancing SC451 and SG293 toward clinical milestones.
Analyze how earnings announcements historically affect stock price performance